View Post

Drug discovered by scientists of NMSU and UNM Cancer Center could lead to new treatments

In Clinical Trials by Barbara Jacoby

Source: NMSU From: krwg.org Fifteen years after a chance meeting started their partnership, a compound Jeffrey Arterburn, and Eric Prossnitz discovered may lead to new skin cancer treatments. Arterburn, a Regents professor in chemistry and biochemistry at New Mexico State University, and Prossnitz, a professor in the Department of Internal Medicine at The University of New Mexico Comprehensive Cancer Center, …

View Post

New study suggests loosening strict comorbidity criteria would open trials to thousands of previously exempt patients

In Clinical Trials by Barbara Jacoby

By: Diane Mapes From: fredhutch.org How do you make cancer clinical trials available to more patients? A new study published today in JAMA Oncology and led by Dr. Joseph Unger at Fred Hutchinson Cancer Research Center offers a tantalizing solution: loosen up the strict eligibility criteria. Low clinical trial participation is a problem that’s plagued cancer researchers for decades, with …

View Post

Can Aligning Radiotherapy for Breast V\Cancer with Circadian Rhythms Minimize Side Effects?

In In The News by Barbara Jacoby

By: Sarah Rosenthal From: medshadow.org Radiation, or radiotherapy, for breast cancer patients is one of the most common forms of treatment, and comes with some uncomfortable and harmful side effects. A recent study from the University of Leicester in England has demonstrated that side effects can be minimized by changing the time of day that the treatment is provided. Researchers …

View Post

Chemo Disturbs Sleep in Breast Cancer Patients

In In The News by Barbara Jacoby

By: Lorraine L. Janeczko From: oncnet.com Patients treated with chemotherapy have disturbed sleep-wake activity, a prospective study from Hong Kong and Australia confirms. “The first administration of adjuvant chemotherapy is associated with sleep disturbance and sleep-wake activity rhythm disruption among breast cancer patients, while the disturbance and disruption during the last cycle are less severe,” the researchers write in Sleep, …

View Post

Marker Therapeutics Provides Updates of its Lead Clinical Programs

In Clinical Trials by Barbara Jacoby

Source: Marker Therapeutics, Inc. From: prnewswire.com Reports clinical data updates with MultiTAA T cells in lymphoma, multiple myeloma and acute lymphoblastic leukemia Reports completion of enrollment for TPIV200 Phase II study in ovarian cancer Reports interim immunogenicity findings of TPIV200 Phase II study in triple negative breast cancer Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company specializing in the development …

View Post

ADAR1 Enzyme Could Be Target for Cancer Stem Cell Elimination

In In The News by Barbara Jacoby

From: genengnews.com Scientists at the University of California (UC) San Diego School of Medicine report (Hyper-Editing of Cell-Cycle Regulatory and Tumor Suppressor RNA Promotes Malignant Progenitor Propagation) in Cancer Cell that detection of copy editing by stem cell enzyme ADAR1, which is active in more than 20 tumor types, may provide a kind of molecular radar for early detection of …

View Post

First-in-human Study of Precision Immune Stimulant PIN-2 Demonstrated Pharmacologic Activity and Safety in Patients with Advanced Solid Tumors

In Clinical Trials by Barbara Jacoby

Source: PIN Pharma, Inc. From: argus-press.com PIN Pharma, Inc., today announced final results of a first-in-human clinical trial of its novel immunomodulating agent PIN-2 in subjects with advanced solid tumors. This was an open-label, repeat-dose study with a primary objective to assess the pharmacodynamic activity of PIN-2. Pharmacodynamic biomarkers that signal changes in the human immune system were used to …